NCT05065294View on ClinicalTrials.gov

Psilocybin Therapy for Depression in Bipolar II Disorder

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

January 28, 2022

Primary Completion Date

August 1, 2024

Study Completion Date

July 31, 2025

Conditions
Bipolar II Disorder
Interventions
DRUG

Psilocybin therapy

\- Psilocybin administration session 10mg-25mg delivered orally with psychological support and monitoring

Trial Locations (1)

94121

University of California, San Francisco, San Francisco

All Listed Sponsors
lead

University of California, San Francisco

OTHER